ESR1 and breast cancer: Triple‐negative breast cancer (TNBC), which lacks expression of classically estrogen receptor (ER) and progesterone receptor (PR) and human epidermal growth factor receptor‐2 (HER‐2) amplification, makes up 15–20% of all breast cancer cases.